Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNMA1 | Q12791 | 12/20 | 0.60 |
| ▸ | P4HTM | Q9NXG6 | 3/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15019034 | 0.92 | KCNMA1 (0.57) | KCNMA1P4HTMHDAC1MEN1NPC1 | |
| SCHEMBL16209414 | 0.90 | P4HTM (0.51) | KCNMA1P4HTMMEN1NPC1RAB9A | |
| SCHEMBL16209714 | 0.85 | KCNMA1 (0.51) | KCNMA1P4HTMHDAC1MEN1NPC1 | |
| SCHEMBL16210280 | 0.82 | P4HTM (0.47) | KCNMA1P4HTMMEN1NPC1RAB9A | |
| SCHEMBL16209682 | 0.81 | KMT2A (0.51) | KCNMA1P4HTMMEN1NPC1RAB9A | |
| SCHEMBL15019683 | 0.81 | P4HTM (0.56) | P4HTMHDAC1MEN1NPC1RAB9A | |
| SCHEMBL16209987 | 0.81 | ALDH1A1 (0.42) | KCNMA1P4HTMMEN1NPC1RAB9A | |
| SCHEMBL16209468 | 0.80 | MAOB (0.54) | P4HTMMEN1NPC1RAB9AKMT2A | |
| SCHEMBL16210174 | 0.80 | P4HTM (0.54) | P4HTMMEN1NPC1RAB9AKMT2A | |
| SCHEMBL15019284 | 0.79 | P4HTM (0.47) | P4HTMMEN1NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140329854-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL IN SIRTUIN BINDING AND MODULATION | SMB INNOVATION (US) | 2014-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329854-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL IN SIRTUIN BINDING AND MODULATION | SIRT1, SIRT3, SIRT2 | KCNMA1 3946/4885P4HTM 2015/4885HDAC1 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.